The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes

E. J. Duncavage, B. Tandon

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations

Abstract

Myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are a heterogeneous group of disorders that share a common biology and are a major source of morbidity and mortality. In the last several years, studies using next-generation sequencing (NGS) have identified a core set of recurrently mutated myeloid malignancy genes in the majority of patients with AML and MDS, including those with normal cytogenetics. DNA-level mutations in several of these genes including NPM1, FLT3, and CEBPA in AML and ASXL1, ETV6, EZH2, RUNX1, and TP53 in MDS are associated with changes in patient outcomes and are now tested for in clinical laboratories. In addition to providing prognostic information, these gene mutations can be used to monitor patient disease burden through the use of ultrasensitive detection techniques. In this review, we will focus on the clinical utility of various NGS-based methods including whole-genome sequencing, exome sequencing, and targeted panel-based sequencing in the initial diagnosis and management of AML and MDS and cover recent methodological advances for the molecular monitoring of AML and MDS.

Original languageEnglish
Pages (from-to)115-121
Number of pages7
JournalInternational Journal of Laboratory Hematology
Volume37
Issue numberS1
DOIs
StatePublished - May 1 2015

Keywords

  • Acute myeloid leukemia
  • Clinical diagnostics
  • Minimal residual disease
  • Myelodysplastic syndrome
  • Next-generation sequencing

Fingerprint

Dive into the research topics of 'The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this